Jim Cramer’s 4 stock ideas from JPMorgan Healthcare Conference
Health care may be a real challenger to tech this year, a business that can actually grow faster than most of tech and has the possibility of a comeback from …
Amgen Inc
Apple longtime directors Al Gore and James Bell retiring from board
Former Vice President Al Gore speaks during the Agriculture Innovation Mission (AIM) for Climate Summit at the JW Marriott on May 08, 2023 in Washington, DC. Chip Somodevilla | Getty …
Walgreens and 3 other health-care stocks are going into our Bullpen watch list
We’re making our first Bullpen update of 2024. The Bullpen is a collection of stocks identified by the CNBC Investing Club team as having the potential to join Jim Cramer’s …
Follow CEOs at the JPMorgan Healthcare Conference
CNBC’s Jim Cramer on Friday told investors what to watch for on Wall Street next week, highlighting JPMorgan‘s market-moving health-care conference in San Francisco. Taking place from Monday to Thursday, …
Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. As these new therapies begin treating patients, some investors see better times ahead next year. “We’ve …
Oprah’s flip on weight loss drugs is a sign of what’s to come for the ‘Ozempic trade’ in 2024
For many struggling with obesity, new medications have been “a gift,” as Oprah Winfrey recently described it in declaring she was “done with the shaming.” Investors in drug manufacturers Novo …
Pharma had a year full of firsts
Soumyabrata Roy | Nurphoto | Getty Images Drugmakers are closing out a year when they achieved several historic firsts that will shape the pharmaceutical industry in 2024 and beyond. The …
2024 expectations for Wegovy, Ozempic, Zepbound
George Frey | Bloomberg | Getty Images Weight loss drugs exploded into the public eye this year, and 2024 will bring more change to the evolving market. The drugs skyrocketed …
Where M&A could be heading in the obesity drug space
Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk and Eli Lilly have the growing obesity drug market all to …
Why Pfizer’s stumble in the obesity market is a boon for Eli Lilly
Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that’s good news for Club holding Eli Lilly (LLY) as it looks to maintain …